SCHEMBL13249873

SCHEMBL13249873

Cc1nc2c(c(=O)n1C(c1ccccc1)c1ccccc1)CCN(C(=O)COc1ccccc1)C2

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ L3MBTL1 Q9Y468 3/20 0.44
▸ TAAR1 Q96RJ0 1/20 0.43
▸ PRLHR P49683 4/20 0.42
▸ TDP1 Q9NUW8 2/20 0.41
▸ GAA P10253 2/20 0.41
▸ MAPT P10636 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ PTGDR2 Q9Y5Y4 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ LDHA P00338 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13249891 0.90 CYP3A4 (0.46) MEN1KMT2APRLHRGAAUSP2
SCHEMBL13249890 0.89 NPC1 (0.40) MEN1KMT2AGAAKDM4EUSP2
SCHEMBL13249900 0.88 PTGDR2 (0.38) MEN1KMT2APRLHRKDM4EUSP2
SCHEMBL13249901 0.88 NPC1 (0.40) MEN1KMT2APRLHRUSP2PTGDR2
SCHEMBL16328070 0.85 NPC1 (0.38) MEN1KMT2APRLHRMAPTUSP2
SCHEMBL13249795 0.85 MGLL (0.47) GAAUSP2TSHRSMN1; SMN2ALDH1A1
SCHEMBL13249834 0.85 ALDH1A1 (0.42) MEN1KMT2ATAAR1GAAMAPT
SCHEMBL13249847 0.85 NPC1 (0.42) MEN1KMT2AKDM4EPTGDR2TSHR
SCHEMBL13249892 0.84 PTGDR2 (0.41) MEN1KMT2APTGDR2HPGDTSHR
SCHEMBL13249786 0.84 TSHR (0.45) MEN1KMT2AGAAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190687-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION 2010-07-29 — — US disclosed
US-20100190687-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION 2010-07-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190687-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF GPR119, GCGR, GPR65 MEN1 3247/4885KMT2A 2108/4885L3MBTL1 4263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback